RayKnowChina Research Map
Shortlist

BeijingCapital Medical University

Beijing Chao-Yang Hospital

首都医科大学附属北京朝阳医院

Listed for 28 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Beijing Chao-Yang Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌8 papers led
  2. Hepatocellular carcinoma肝细胞癌18 papers led
  3. Stomach cancer胃癌12 papers led
  4. Lung cancer肺癌66 papers led2 open trials led
  5. Pancreatic cancer胰腺癌18 papers led
  6. Breast cancer乳腺癌21 papers led
  7. Chordoma脊索瘤2 papers led
  8. Osteosarcoma骨肉瘤6 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  10. Neuroblastoma神经母细胞瘤1 paper led
  11. Ewing sarcoma尤文肉瘤2 papers led
  12. Multiple myeloma多发性骨髓瘤52 papers led
  13. Lymphoma淋巴瘤2 papers led
  14. Beta thalassaemiaβ 地中海贫血0 papers led
  15. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征0 papers led
  16. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
  17. Coronary heart disease冠心病34 papers led2 open trials led
  18. Congenital heart disease先天性心脏病3 papers led
  19. Scoliosis脊柱侧弯40 papers led
  20. Takayasu arteritis大动脉炎3 papers led
  21. Idiopathic pulmonary fibrosis特发性肺纤维化13 papers led
  22. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  23. Behçet disease白塞病1 paper led
  24. IgA nephropathyIgA 肾病4 papers led
  25. Primary biliary cholangitis原发性胆汁性胆管炎3 papers led
  26. Primary sclerosing cholangitis原发性硬化性胆管炎2 papers led
  27. Congenital diaphragmatic hernia先天性膈疝1 paper led
  28. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Nasopharyngeal carcinoma, Glioma, Hepatoblastoma, Retinoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 8 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 3320242025: 112025

13 hospitals in Beijing for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapyMolecular markers & genomics
Departments in papersPathology / laboratory medicineMedical oncology
Papers it led8
  1. p53 and Ki-67 combined with periodic acid-Schiff staining for the diagnosis of early stage esophageal squamous cell carcinoma lesions in biopsy specimens.2025Esophagus : official journal of the Japan Esophageal SocietyFree full text
  2. Phospholipase PLCE1 Promotes Transcription and Phosphorylation of MCM7 to Drive Tumor Progression in Esophageal Cancer.2024Cancer research
  3. Expression and correlation of PD-L1 and HER2 in oesophageal squamous cell carcinoma.2024Journal of clinical pathology
  4. Correlation of PD-L1 expression with CD8+ T cells and oxidative stress-related molecules NRF2 and NQO1 in esophageal squamous cell carcinoma.2024The journal of pathology. Clinical researchFree full text
  5. Preventive Treatment with PD-1 Antibody Increases Tissue-resident Memory T Cells Infiltration and Delays Esophageal Carcinogenesis.2023Cancer prevention research (Philadelphia, Pa.)Free full text
  6. APOC1 predicts a worse prognosis for esophageal squamous cell carcinoma and is associated with tumor immune infiltration during tumorigenesis.2023Pathology oncology research : PORFree full text
  7. High expression of nuclear NRF2 combined with NFE2L2 alterations predicts poor prognosis in esophageal squamous cell carcinoma patients.2022Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  8. DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway.2021Molecular cancer research : MCR
More papers found outside PubMed (not counted)12
  1. 193P DCLK1’s kinase activity drives its pro-stemness effect in esophageal squamous cell carcinoma2024Annals of Oncologyarticle
  2. Data from DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway2023Venue not listedother
  3. Supplementary Figure 4 from DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway2023Venue not listedsupplementary-materials
  4. Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  5. Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  6. Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  7. Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  8. Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  9. Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  10. Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  11. RETRACTED ARTICLE: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling2022Figsharedataset
  12. Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 18 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
18
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 5520222023: 5520232024: 4420242025: 112025

17 hospitals in Beijing for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisSurgery & liver transplantLocal treatment (ablation, TACE, HAIC)
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine
Papers it led18
  1. Integrated analysis and experimental validation reveal the prognostic and immunological features associated with coagulation in hepatocellular carcinoma.2025Scientific reportsFree full text
  2. LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy.2024Cell death & diseaseFree full text
  3. Impact of metabolic dysfunction-associated fatty liver disease on liver transplant recipients with hepatitis B virus-related hepatocellular carcinoma.2024European journal of clinical nutrition
  4. Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma.2024Frontiers in endocrinologyFree full text
  5. Anti-PD-1 therapy reverses TIGIT+CD226+NK depletion in immunotherapy resistance of hepatocellular carcinoma through PVR/TIGIT pathway.2024International immunopharmacology
  6. Metformin promotes the normalization of abnormal blood vessels after radiofrequency ablation deficiency in hepatocellular carcinoma by microRNA-302b-3p targeting thioredoxin-interacting protein.2023Acta biochimica Polonica
  7. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.2023Cancer biology & medicineFree full text
  8. Therapeutically targeting essential metabolites to improve immunometabolism manipulation after liver transplantation for hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  9. Preoperative systemic inflammatory response index predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation.2023Frontiers in immunologyFree full text
  10. Unveiling the Mystery of SUMO-activating enzyme subunit 1: A Groundbreaking Biomarker in the Early Detection and Advancement of Hepatocellular Carcinoma.2023Transplantation proceedings
  11. Prognosis of Liver Transplantation for Hepatocellular Carcinoma in Terms of Different Criteria: A Single Center Experience.2022Current medical science
  12. Anatomic resection versus radiofrequency ablation with an ablative margin ≥ 1.0 cm for solitary small hepatocellular carcinoma measuring ≤ 3 cm: Comparison of long-term outcomes using propensity score matching analysis.2022European journal of radiology
  13. Safety and efficacy of microwave versus radiofrequency ablation for large hepatic hemangioma: a multicenter retrospective study with propensity score matching.2022European radiology
  14. Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  15. Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1α-mediated glycolysis in hepatocellular carcinoma.2022World journal of gastroenterologyFree full text
  16. Intrahepatic hemorrhage and recurrence caused by arterioportal fistula after radiofrequency ablation for hepatocellular carcinoma: A thought-provoking ablation-related complication.2021Asian journal of surgery
  17. The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation.2021MedicineFree full text
  18. PD-L1+NEUT, Foxp3+Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma.2021Technology in cancer research & treatmentFree full text
Chinese-language papers (not in the count)1
  1. [Angio-associated migratory cell protein is highly expressed in hepatocellular carcinoma and promotes tumor cell invasion and metastasis].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular CarcinomaCompletedNCT00300521Lead sponsorPhase 2Start 2000-09

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 12 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 1120232024: 4420242025: 222025

16 hospitals in Beijing for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNutrition & recoveryPeritoneal spread & advanced diseaseImaging & AI
Departments in papersPathology / laboratory medicineGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine
Papers it led12
  1. Lipidomic machine learning predictor for progression of gastric cancer.2026Clinica chimica acta; international journal of clinical chemistry
  2. Clinicopathological features and mucin expression of early papillary gastric adenocarcinoma.2025Scientific reportsFree full text
  3. Diagnostic Value of Joint Detection of Serum TK1, TSGF, CA199, and CA724 for Gastric Cancer and Its Relationship With Clinicopathologic Features and Prognosis.2025The American surgeon
  4. GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration.2024Cancer immunology, immunotherapy : CIIFree full text
  5. Gastric Cancer Immune Subtypes and Prognostic Modeling: Insights from Aging-Related Gene Analysis.2024Critical reviews in immunology
  6. Advanced Gastric Cancer: CT Radiomics Prediction of Lymph Modes Metastasis After Neoadjuvant Chemotherapy.2024Journal of imaging informatics in medicineFree full text
  7. DNA methylation profiling identifies epigenetic signatures of early gastric cancer.2024Virchows Archiv : an international journal of pathology
  8. Multimodality Therapy, Followed by Laparoscopic Gastrectomy, for Unresectable Gastric Cancer With Outlet Obstruction and Bulky N2 Metastases.2023Surgical laparoscopy, endoscopy & percutaneous techniques
  9. Clinicopathological and molecular characteristics of the alpha-fetoprotein-producing gastric cancer: emphasis on two major subtypes.2022APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  10. Deep learning for automatic diagnosis of gastric dysplasia using whole-slide histopathology images in endoscopic specimens.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  11. Silencing of ER-resident oxidoreductase PDIA3 inhibits malignant biological behaviors of multidrug-resistant gastric cancer.2021Acta biochimica et biophysica Sinica
  12. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
Chinese-language papers (not in the count)6
  1. [Neuroendocrine carcinoma with significantly vacuolar nucleus at the esophagogastric junction: A case report].2025Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciencesFree full text
  2. [Clinicopathological features of Helicobacter pylori-negative early gastric cancer].2023Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciencesFree full text
  3. [The value of Alcian blue periodic acid Schiff staining and Ki-67 expression in diagnosing gastric reactive epithelial hyperplasia and dysplasia].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Clinicopathological features of early gastric cancer after Helicobacter pylori eradication].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  5. [Clinicopathological features of very well-differentiated adenocarcinoma of the stomach].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  6. [Application and Progress of Convolutional Neural Network-based Pathological Diagnosis of Gastric Cancer].2021Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science editionFree full text
All its trials on ClinicalTrials.gov, any status5
  1. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  2. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  3. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  4. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  5. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Study siteStart 2017-12

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 66 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
66
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 6620212022: 161620222023: 191920232024: 191920242025: 662025

20 hospitals in Beijing for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT06950697

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Chao-Yang Hospital; 2 listed hospitals as study sitesBeijing, Zhengzhou

  2. Not yet recruiting
    Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07882628

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Chao-Yang Hospital; 4 listed hospitals as study sitesBeijing, Changsha

  3. Recruiting
    Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
    Phase
    Phase 3
    Started
    2026-08
    Posted
    Registry
    NCT07778316

    Age 18 years to 99 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  4. Recruiting
    A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05913089

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Fuzhou, Shanghai, Taiyuan, Tianjin, Weifang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicineMedical oncologySurgery (general/hepatobiliary/pancreatic)
Papers it led66
  1. Effect of Co-Administration of Midazolam and Dexmedetomidine on Haemodynamics and Stress Response in Elderly Patients with Non-Small Cell Lung Cancer.2025Journal of investigative surgery : the official journal of the Academy of Surgical ResearchRCT
  2. Immune checkpoint inhibitors for advanced non-small cell lung cancer with preexisting COPD and CT-defined emphysema: A systematic review and meta-analysis.2025Lung cancer (Amsterdam, Netherlands)
  3. The association and impact of radiographic, pathological emphysema and spirometric airway obstruction on patients with resectable lung adenocarcinoma.2025Respiratory researchFree full text
  4. Restoration of A2M reduces drug resistance and malignancy in paclitaxel-resistant lung cancer cells.2025The international journal of biochemistry & cell biology
  5. Association of Baseline Serum Uric Acid With Venous Thromboembolism and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer.2025Thoracic cancerFree full text
  6. An Observational Study Evaluating the Safety of Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients Undergoing Surgery for Non-Small Cell Lung Cancer.2025Thoracic cancerFree full text
  7. Comprehensive profiling of serum glycosphingolipids to discover the diagnostic biomarkers of lung cancer and uncover the variation of glycosphingolipid networks in different lung cancer subtypes.2024Analytical methods : advancing methods and applications
  8. Association of potentially inappropriate medications with prognosis among older patients with non-small cell lung cancer.2024BMC geriatricsFree full text
  9. Prognostic and predictive value of interstitial lung abnormalities and EGFR mutation status in patients with non-small cell lung cancer.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  10. Identification of Crosstalk Genes between Lung Adenocarcinoma and Periodontitis.2024Current medicinal chemistry
  11. Comparison of four criteria for potentially inappropriate medications in older patients with newly diagnosed non-small cell lung cancer.2024Expert opinion on drug safety
  12. Liraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps.2024FEBS open bioFree full text
  13. Synchronous multiple myeloma and lung adenocarcinoma: A clinical series.2024Indian journal of pathology & microbiology
  14. Clinical and Pathological Characteristics and Prognosis of Lung Adenocarcinoma With High-Grade Fetal Features: A Retrospective Analysis.2024International journal of surgical pathology
  15. Survival prediction in sigmoid colon cancer patients with liver metastasis: a prospective cohort study.2024JNCI cancer spectrumFree full text
  16. EML4-ALK fusion protein in Lung cancer cells enhances venous thrombogenicity through the pERK1/2-AP-1-tissue factor axis.2024Journal of thrombosis and thrombolysisFree full text
  17. Long Noncoding RNA MSL3P1 Regulates CUL3 mRNA Cytoplasmic Transport and Stability and Promotes Lung Adenocarcinoma Metastasis.2024Molecular cancer research : MCR
  18. The clinicopathological features of lung metastases of parathyroid cancinoma.2024Pathology, research and practice
  19. Semi-supervised lung adenocarcinoma histopathology image classification based on multi-teacher knowledge distillation.2024Physics in medicine and biology
  20. Integrated omics characterization reveals reduced cancer indicators and elevated inflammatory factors after thermal ablation in non-small cell lung cancer patients.2024Respiratory researchFree full text
  21. Prognostic, immunity, stemness, and anticancer drug sensitivity characterization of pyroptosis related genes in non-small cell lung cancer.2024Thoracic cancerFree full text
  22. Enhancing surgical precision in early-stage non-small cell lung cancer: A novel approach through temporary pulmonary vascular occlusion.2024Thoracic cancerFree full text
  23. Is wedge resection equivalent to segmentectomy in pathological stage IA (≤2 cm) non-small cell lung cancers?2024Thoracic cancerFree full text
  24. A liquid biopsy assay for the noninvasive detection of lymph node metastases in T1 lung adenocarcinoma.2024Thoracic cancerFree full text
  25. Surgical outcomes for non-small cell lung cancer in younger adults: A population-based study.2024Thoracic cancerFree full text
  26. Construction and validation of a hypoxia-related risk signature identified EXO1 as a prognostic biomarker based on 12 genes in lung adenocarcinoma.2023AgingFree full text
  27. Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage I-III lung adenocarcinoma patients.2023Animal models and experimental medicineFree full text
  28. Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report.2023Anti-cancer drugsFree full text
  29. Predicting survival for patients with mesothelioma: development of the PLACE prognostic model.2023BMC cancerFree full text
  30. High accuracy epidermal growth factor receptor mutation prediction via histopathological deep learning.2023BMC pulmonary medicineFree full text
  31. Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis.2023BMJ openFree full text
  32. Development and validation of a nomogram to assess postoperative venous thromboembolism risk in patients with stage IA non-small cell lung cancer.2023Cancer medicineRCTFree full text
  33. Interstitial pneumonitis associated with EGFR/ ALK tyrosine kinase inhibitors used in non-small cell lung cancer: an observational, retrospective, pharmacovigilance study.2023Expert opinion on drug safety
  34. Risks of cardiovascular toxicities associated with ALK tyrosine kinase inhibitors in patients with non-small-cell lung cancer: a meta-analysis of randomized control trials.2023Expert opinion on drug safety
  35. Echocardiographic Characteristics of Pulmonary Artery Intimal Sarcoma: Comparison With CTPA.2023Heart, lung & circulation
  36. Clinical, laboratory, pathological, and radiological characteristics and prognosis of patients with pulmonary salivary gland-type tumors.2023Journal of cancer research and clinical oncologyFree full text
  37. Pulmonary artery sarcoma: an unexpected settler in the right ventricular outflow tract.2023Journal of cardiothoracic surgeryFree full text
  38. Clinical role of serum tumor markers SCC, NSE, CA 125, CA 19-9, and CYFRA 21-1 in patients with lung cancer.2023Laboratory medicine
  39. Validation of the novel International Association for the Study of Lung Cancer grading system and prognostic value of filigree micropapillary and discohesive growth pattern in invasive pulmonary adenocarcinoma.2023Lung cancer (Amsterdam, Netherlands)
  40. Characterization of the alternative splicing landscape in lung adenocarcinoma reveals novel prognosis signature associated with B cells.2023PloS oneFree full text
  41. Malignant peritoneal mesothelioma.2023The American journal of the medical sciences
  42. Radiofrequency ablation for stage <IIB non-small cell lung cancer: Opportunities, challenges, and the road ahead.2023Thoracic cancerFree full text
  43. Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1.2023Thoracic cancerFree full text
  44. Newly diagnosed non-small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis.2023Thoracic cancerFree full text
  45. Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness.2022Cancer letters
  46. Prognostic impact of pleural effusion in patients with malignancy: A systematic review and meta-analysis.2022Clinical and translational scienceFree full text
  47. Clinical Features and Outcomes of Pulmonary Artery Sarcoma.2022Heart, lung & circulation
  48. KAT2A affects tumor metabolic reprogramming in colon cancer progression through epigenetic activation of E2F1.2022Human cell
  49. Validation of a modified Caprini risk assessment model in lung cancer patients undergoing surgery: Results of a multicenter cross-sectional observational study.2022Journal of surgical oncology
  50. Early detection of COPD based on graph convolutional network and small and weakly labeled data.2022Medical & biological engineering & computingFree full text
  51. Clinical, Laboratory, Histological, Radiological, and Metabolic Features and Prognosis of Malignant Pleural Mesothelioma.2022Medicina (Kaunas, Lithuania)Free full text
  52. Real-world data of EGFR mutation testing in Chinese non-small cell carcinoma: Low tumor cell number and tumor cellularity can be accepted.2022Pathology, research and practice
  53. Assessment of the association between periodontal disease and total cancer incidence and mortality: a meta-analysis.2022PeerJFree full text
  54. Establishment of a Competing Risk Nomogram in Patients with Pulmonary Sarcomatoid Carcinoma.2022Technology in cancer research & treatmentFree full text
  55. Correlation between clinicopathological characteristics of lung adenocarcinoma and the risk of venous thromboembolism.2022Thoracic cancerFree full text
  56. A case of multiple primary lung adenocarcinoma with a CD74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy.2022Thoracic cancerFree full text
  57. A comprehensive study of alternative splicing in malignant pleural mesothelioma identifies potential therapeutic targets in a new cluster with poor survival.2022Thoracic cancerFree full text
  58. Postoperative venous thromboembolism after surgery for stage IA non-small-cell lung cancer: A single-center, prospective cohort study.2022Thoracic cancerFree full text
  59. SCLC and anti-GABABR encephalitis: A retrospective analysis of 60 cases in China.2022Thoracic cancerFree full text
  60. Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials.2022Thrombosis and haemostasis
  61. Myocardial Glucose Metabolism Is Increased in Newly Diagnosed Lung Adenocarcinoma.2021Cardiology
  62. Single-cell analysis of diverse immune phenotypes in malignant pleural effusion.2021Nature communicationsFree full text
  63. Prediction modeling using routine clinical parameters to stratify survival in malignant pleural mesothelioma patients complicated with malignant pleural effusion.2021Thoracic cancerFree full text
  64. Evaluation of dual-energy and perfusion CT parameters for diagnosing solitary pulmonary nodules.2021Thoracic cancerFree full text
  65. Development and validation of tumor-to-blood based nomograms for preoperative prediction of lymph node metastasis in lung cancer.2021Thoracic cancerFree full text
  66. Development and validation of a predictive score for venous thromboembolism in newly diagnosed non-small cell lung cancer.2021Thrombosis research
Chinese-language papers (not in the count)9
  1. [A case of pulmonary nodules and cysts associated with hypereosinophilia].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  2. [Application of artificial intelligence in combination with CT radiomics in chronic obstructive pulmonary disease].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  3. [Evaluation of the short-term efficacy of fluorescence thoracoscopy-assisted temporary occlusion of pulmonary arteries and veins in sublobar resection for early-stage non-small cell lung cancer].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  4. [Multiple pulmonary nodules with cavity formation].2024Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  5. [Multiple pulmonary nodules with interstitial changes].2022Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  6. [Detection of circulating tumor cells with chromosomes 7 and 8 polysomy in non-small cell lung cancer and its correlation with epidermal growth factor receptor mutations in cancer tissue].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
  7. [Asbestos exposure and asbestos-related malignant diseases:an epidemiological review].2021Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
  8. [Recommendations for the management of malignant pleural mesothelioma].2021Zhonghua nei ke za zhi
  9. [Analysis of incidence and risk factors for postoperative venous thromboembolism in patients with stageⅠ a non-small-cell lung cancer].2021Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status18
  1. Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung CancerNot yet recruitingNCT07882628Lead sponsorStart 2026-10
  2. Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint InhibitorsRecruitingNCT06950697Lead sponsorStart 2019-01
  3. A Study Developing a Non-invasive Urine-based Proteomic Model for Early Lung Cancer Detection.Status unknownNCT06733311Lead sponsorStart 2024-03
  4. Study of Changes of Lymphocyte Subsets in Chemotherapy Course of Patients With Non-small Cell Lung CancerStatus unknownNCT02202655Lead sponsorStart 2014-05
  5. Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)RecruitingNCT07778316Study sitePhase 3Start 2026-08
  6. A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung CancerRecruitingNCT05913089Study sitePhase 2Start 2023-06
  7. Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabActive, not recruitingNCT06211036Study sitePhase 3Start 2024-06
  8. A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerTerminatedNCT04746924Study sitePhase 3Start 2021-05
  9. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  10. HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung CancerStatus unknownNCT04750083Study sitePhase 2/Phase 3Start 2020-09
  11. A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive BiomarkersStatus unknownNCT04462185Study siteStart 2020-07
  12. A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLCStatus unknownNCT04033354Study sitePhase 3Start 2019-08
  13. eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsActive, not recruitingNCT02767804Study sitePhase 3Start 2016-06
  14. Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung AdenocarcinomaStatus unknownNCT02125240Study sitePhase 3Start 2014-09
  15. VATS Major Lung Resection for Chinese Early-stage Non-small Cell Lung CancerStatus unknownNCT01707888Study siteStart 2014-09
  16. BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)CompletedNCT01121393Study sitePhase 3Start 2010-04
  17. Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) PatientsCompletedNCT01040780Study sitePhase 3Start 2009-02
  18. Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung CancerCompletedNCT00883675Study sitePhase 4Start 2009-05

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 18 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
18
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 4420222023: 4420232024: 0020242025: 772025

17 hospitals in Beijing for pancreatic cancer192 hospitals in China for pancreatic cancer

No open trial on pancreatic cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineMedical oncology
Papers it led18
  1. Ultrasound-Mediated Piezocatalysis Triggers NO Release to Augment Targeted Immunotherapy of Pancreatic Cancer.2025ACS nano
  2. A logistic regression model to predict long-term survival for borderline resectable pancreatic cancer patients with upfront surgery.2025Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  3. Radiomics-based histological grading of pancreatic ductal adenocarcinoma using 18F-FDG PET/CT: A two-center study.2025European journal of radiology
  4. Organ-specific role of neutrophil extracellular traps in shaping the postoperative thrombo-inflammatory niche in pancreatic ductal adenocarcinoma: a multi-model machine learning and mechanistic study.2025Frontiers in immunologyFree full text
  5. Utilizing bifurcated allogeneic vein grafts: a novel approach for preventing sinistral portal hypertension following pancreaticoduodenectomy. A 10-year before and after study.2025International journal of surgery (London, England)Free full text
  6. Mesenteric approach for borderline resectable pancreatic head cancer: a 13-Year retrospective cohort study.2025Langenbeck's archives of surgeryFree full text
  7. Development and validation of a predictive model for portal-systemic venous invasion grading in borderline resectable pancreatic cancer.2025World journal of gastroenterologyFree full text
  8. Is new risk-assessment score of venous thromboembolism for hospitalized surgical patients with borderline resectable pancreatic adenocarcinoma needed?2023Asian journal of surgery
  9. A patient with locally advanced pancreatic carcinoma achieved good prognosis after surgery.2023Asian journal of surgery
  10. The coagulation-related genes for prognosis and tumor microenvironment in pancreatic ductal adenocarcinoma.2023BMC cancerFree full text
  11. Prognostic value of perioperative serum low-density lipoprotein cholesterol level for postoperative prognosis of pancreatic cancer: a retrospective study.2023Lipids in health and diseaseFree full text
  12. Impact of the lymph-node parameter on prognosis of patients with pancreatic ductal adenocarcinoma after radical resection.2022Asian journal of surgery
  13. Construction and Validation of a Necroptosis-Related Gene Signature for Predicting Prognosis and Tumor Microenvironment of Pancreatic Cancer.2022Disease markersFree full text
  14. Chemical Exchange Saturation Transfer for Pancreatic Ductal Adenocarcinoma Evaluation.2022Pancreas
  15. Ratio of CA19-9 Level to Total Tumor Volume as a Prognostic Predictor of Pancreatic Carcinoma After Curative Resection.2022Technology in cancer research & treatmentFree full text
  16. Correlation analysis of CA19-9/Glutamyltransferase ratio and long-term survival for patients with pancreatic head cancer under different bilirubin levels.2021Asian journal of surgery
  17. Reconstructing spleno-mesenterico-portal cofluence by bifurcated allogeneic vein in local advanced pancreatic cancer-a feasible method to avoid left-sided portal hypertension.2021Cancer medicineFree full text
  18. Single-cell transcriptomics reveals heterogeneous progression and EGFR activation in pancreatic adenosquamous carcinoma.2021International journal of biological sciencesFree full text
Chinese-language papers (not in the count)1
  1. [Doublecortin-like kinase 1 activates Hippo pathway to promote migration, invasion and proliferation of pancreatic cancer cells].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 21 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
21
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 5520222023: 5520232024: 6620242025: 112025

20 hospitals in Beijing for breast cancer219 hospitals in China for breast cancer

No open trial on breast cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicineRadiology / nuclear medicineOphthalmology / neuro-ophthalmology
Papers it led21
  1. Rivaroxaban Prophylaxis in Peripherally Inserted Central Catheter-Related Thrombosis in Breast Cancer Patients.2025Archives of medical research
  2. Complications After Prepectoral Versus Subpectoral Breast Reconstruction in Patients Receiving Postmastectomy Radiation Therapy: A Systematic Review and Meta-Analysis.2024Aesthetic plastic surgery
  3. Short-term effects of a new resistance exercise approach on physical function during chemotherapy after radical breast cancer surgery: a randomized controlled trial.2024BMC women's healthRCTFree full text
  4. ZNF623 contributes to breast carcinoma progress by recruiting CtBP1 to regulate NF-κB pathway.2024Biochemical and biophysical research communications
  5. Integrative analysis of homologous recombination repair patterns unveils prognostic signatures and immunotherapeutic insights in breast cancer.2024Journal of applied geneticsFree full text
  6. Targeting Tn Antigen Suppresses Aberrant O-Glycosylation-Elicited Metastasis in Breast Cancer.2024Journal of cellular and molecular medicineFree full text
  7. The small nucleolar RNA SNORA51 enhances breast cancer stem cell-like properties via the RPL3/NPM1/c-MYC pathway.2024Molecular carcinogenesis
  8. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.2023Breast cancer research : BCRFree full text
  9. Tn antigen promotes breast cancer metastasis via impairment of CASC4.2023Cell biology international
  10. ST6GALNAC1 promotes the invasion and migration of breast cancer cells via the EMT pathway.2023Genes & genomics
  11. Long Non-coding RNA LINC00473 Promotes Breast Cancer Progression via miR-424-5p/CCNE1 Pathway.2023Protein and peptide letters
  12. Axillary Downstaging and the Impact of Clinical Axillary Status on Efficacy of Neoadjuvant Therapy for HER2-Positive Breast Cancer: A Network Meta-Analysis.2023Technology in cancer research & treatmentFree full text
  13. Development of a Cancer-Associated Fibroblast-Related Prognostic Model in Breast Cancer via Bulk and Single-Cell RNA Sequencing.2022BioMed research internationalFree full text
  14. Paclitaxel-nanocrystals-loaded network thermosensitive hydrogel for localised postsurgical recurrent of breast cancer after surgical resection.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  15. Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials.2022Breast (Edinburgh, Scotland)Free full text
  16. Changes in epicardial adipose tissue among women treated with trastuzumab for breast cancer.2022International journal of cardiology
  17. Assessment of the association between periodontal disease and total cancer incidence and mortality: a meta-analysis.2022PeerJFree full text
  18. Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review.2021Breast (Edinburgh, Scotland)Free full text
  19. Diagnostic value of sialyl-Tn immunocytochemistry in breast cancer presenting with pathological nipple discharge.2021Cancer medicineFree full text
  20. Clinical practice guidelines for post-mastectomy breast reconstruction: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021.2021Chinese medical journalFree full text
  21. Detection significance of miR-3662, miR-146a, and miR-1290 in serum exosomes of breast cancer patients.2021Journal of cancer research and therapeutics
Chinese-language papers (not in the count)2
  1. [Mid-term analysis of prospective cohort study of rivaroxaban in preventing CRT in breast cancer].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. [Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status11
  1. Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast CancerStatus unknownNCT06539559Lead (inferred)Phase 2Start 2024-08
  2. GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast CancerCompletedNCT05054751Study sitePhase 3Start 2021-09
  3. Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABCStatus unknownNCT05343117Study siteStart 2021-12
  4. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  5. Light-CT in the Diagnosis of Breast Tumor and Lymph NodeStatus unknownNCT03791853Study siteStart 2018-04
  6. Ultrasound-based Breast Cancer Screening in Chinese WomenStatus unknownNCT02268643Study siteStart 2014-01
  7. Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative EndocrinotherapyStatus unknownNCT01613560Study sitePhase 2Start 2012-05
  8. Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast CancerStatus unknownNCT01492556Study sitePhase 2Start 2011-12
  9. Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary ChemotherapyStatus unknownNCT01019616Study sitePhase 3Start 2011-03
  10. Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast CancerStatus unknownNCT01492543Study sitePhase 2Start 2011-12
  11. Ultrasound and Mammography for Screening Breast Cancer in Chinese WomenCompletedNCT01880853Study siteN/AStart 2008-11

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 2 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 1.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

9 hospitals in Beijing for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 6 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 112025

38 hospitals in Beijing for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicineRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

20 hospitals in Beijing for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

23 hospitals in Beijing for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

16 hospitals in Beijing for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 52 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 3.1%.

Papers led
52
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
14
led by another institution
Papers led per year
2021: 111120212022: 7720222023: 9920232024: 171720242025: 772025

14 hospitals in Beijing for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 14

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07518186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an

  3. Recruiting
    Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-03
    Posted
    Registry
    NCT07529782

    Age Not stated to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Suzhou, Tianjin

  4. Recruiting
    Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
    Phase
    Phase 1
    Started
    2026-09
    Posted
    Registry
    NCT07620275

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General Hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  5. Recruiting
    A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07297329

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  6. Recruiting
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06375044

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Tianjin, Zhengzhou

  7. Recruiting
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2024-06
    Posted
    Registry
    NCT06508983

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou

  8. Recruiting
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-06
    Posted
    Registry
    NCT06574568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou

  9. Recruiting
    Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Posted
    Registry
    NCT05565807

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou

  10. Recruiting
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    Phase
    Phase 3
    Started
    2022-09
    Posted
    Registry
    NCT05243797

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou

  11. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Posted
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  12. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

  13. Not yet recruiting
    Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 2
    Started
    2027-12
    Posted
    Registry
    NCT07695740

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  14. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinationsStem cell transplant
Departments in papersPathology / laboratory medicineRadiology / nuclear medicineMedical oncology
Papers it led52
  1. Prognostic Implications of Measurable Residual Disease and Autologous Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia in the Era of Novel Agents.2026Transplantation and cellular therapy
  2. The prognostic impact of 1q21 gain/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China.2025Annals of hematology
  3. Temporal trends and disparities in cardiovascular disease-related mortality among adults with multiple myeloma in the United States, 1999-2023.2025BMC cardiovascular disordersFree full text
  4. Prognostic value of the expression of CD27 and CD117 in newly diagnosed multiple myeloma patients.2025BMC immunologyFree full text
  5. Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi-Center, Open-Label Phase I Trial.2025Cancer medicineFree full text
  6. Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: a retrospective cohort study.2025Hematology (Amsterdam, Netherlands)
  7. Exploring multiple myeloma pathobiology and immune cell signatures: Evidence from bidirectional genetic analysis.2025MedicineFree full text
  8. Analysis of clinical characteristics, treatment response, and prognosis among 67 patients with anaplastic multiple myeloma.2025World journal of surgical oncologyFree full text
  9. Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study.2024Annals of hematology
  10. Prognostic value of 18F-FDG PET/CT in patients with relapsed multiple myeloma.2024Annals of hematology
  11. Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.2024Annals of hematologyFree full text
  12. Myeloma extracellular vesicle-derived RAGE increases inflammatory responses and myotube atrophy in multiple myeloma through activation of the TLR4/NF-κB p65 pathway.2024Apoptosis : an international journal on programmed cell death
  13. Evaluation of the Prognostic Value of the Mayo Additive Staging System and Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients.2024Cancer medicineFree full text
  14. Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.2024Cancer medicineFree full text
  15. KIAA1429 increases FOXM1 expression through YTHDF1-mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma.2024Cell biology and toxicologyFree full text
  16. Detection of lenalidomide metabolites in urine to discover drug-resistant compounds.2024Clinica chimica acta; international journal of clinical chemistry
  17. Proteomics analysis of serum and urine identifies VCP and CTSA as potential biomarkers associated with multiple myeloma.2024Clinica chimica acta; international journal of clinical chemistry
  18. Bone marrow fibrosis in newly diagnosed multiple myeloma and its correlation with clinicopathological factors.2024Diagnostic pathologyFree full text
  19. Analysis of the efficacy of separation surgery for severe neurological compression in multiple myeloma: a retrospective analysis of 35 cases.2024European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  20. Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma.2024Frontiers in immunologyFree full text
  21. Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center.2024Hematology (Amsterdam, Netherlands)
  22. Synchronous multiple myeloma and lung adenocarcinoma: A clinical series.2024Indian journal of pathology & microbiology
  23. Chromosome 1q21 Aberrations Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients.2024Journal of clinical laboratory analysisFree full text
  24. Wound healing after surgical therapy for multiple myeloma: a case-control study.2024Journal of wound care
  25. Which factors are associated with adverse prognosis in multiple myeloma patients after surgery? - preliminary establishment and validation of the nomogram.2024World journal of surgical oncologyFree full text
  26. The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma.2023Advances in therapyFree full text
  27. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.2023BMC cancerRCTFree full text
  28. Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.2023Blood advancesFree full text
  29. Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era.2023Cancer medicineFree full text
  30. Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients.2023Clinical and experimental medicine
  31. In vivo antitumor efficacy of 17-AAG loaded PMMA in a human multiple myeloma xenograft mouse model.2023Clinical and experimental medicine
  32. Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era.2023Hematology (Amsterdam, Netherlands)
  33. Biological research on the occurrence and development of multiple myeloma and its treatment.2023Immunity, inflammation and diseaseFree full text
  34. The effects of nutritional support on cellular immunity of the patient with multiple myeloma undergoing chemotherapy.2023Panminerva medica
  35. Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.2022Advances in therapy
  36. Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation.2022BMC cancerFree full text
  37. Incidence of multiple myeloma in Kailuan cohort: A prospective community-based study in China.2022Cancer epidemiology
  38. Echocardiography-defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients.2022Cancer medicineFree full text
  39. Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study.2022Cancer medicineFree full text
  40. Routine blood biomarkers for the detection of multiple myeloma using machine learning.2022International journal of laboratory hematology
  41. The Association Between Low T3 Syndrome and Survival in Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study.2022Technology in cancer research & treatmentFree full text
  42. Pleural effusion-based nomogram to predict outcomes in unselected patients with multiple myeloma: a large single center experience.2021Annals of hematology
  43. The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.2021BioMed research internationalFree full text
  44. Autologous peripheral blood stem cell transplantation as front-line therapy for myeloma with double-hit and triple-hit in a real-world study.2021Chinese medical journalFree full text
  45. Promoting effects of MiR-135b on human multiple myeloma cells via regulation of the Wnt/β-catenin/Versican signaling pathway.2021Cytokine
  46. The Prevalence of Euthyroid Hypertriiodothyroninemia in Newly Diagnosed Multiple Myeloma and its Clinical Characteristics.2021Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  47. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.2021International journal of hematology
  48. Deep Learning-Based CT Imaging in Diagnosing Myeloma and Its Prognosis Evaluation.2021Journal of healthcare engineeringFree full text
  49. At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.2021Leukemia & lymphoma
  50. Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.2021Leukemia & lymphoma
  51. LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN.2021Neoplasma
  52. Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma.2021Turkish journal of haematology : official journal of Turkish Society of HaematologyFree full text
Chinese-language papers (not in the count)20
  1. [The Influence of COVID-19 Infection on the Mobilization and Collection of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma].2025Zhongguo shi yan xue ye xue za zhi
  2. [Clinical Analysis of Listeriosis in Treatment of Multiple Myeloma with Novel Agents].2025Zhongguo shi yan xue ye xue za zhi
  3. [Analysis of the efficacy of a carfilzomib-based regimen in the treatment of relapsed and refractory multiple myeloma].2025Zhonghua nei ke za zhi
  4. [Advances for treatment of relapsed or refractory multiple myeloma: interpretation of guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].2024Zhonghua nei ke za zhi
  5. [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].2024Zhonghua nei ke za zhi
  6. [Prognostic analysis of 19 newly treated multiple myeloma patients with t(14; 16)].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  7. [Analysis of the prognostic factors in primary plasma cell leukemia in the era of novel agents].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  8. [Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in the mobilization of autologous peripheral blood stem cells in patients with multiple myeloma].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  9. [Minimal residual disease assessment and progress in multiple myeloma].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  10. [MiR-203a-5p Inhibits Multiple Myeloma Cell Proliferation and Cell Cycle Progression via Targeting JAG1].2023Zhongguo shi yan xue ye xue za zhi
  11. [Application and significance of peripheral blood circulating plasma cells in the diagnosis of multiple myeloma].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  12. [Prognostic significance of immunoparesis in newly diagnosed multiple myeloma patients who achieved deep response].2022Zhonghua nei ke za zhi
  13. [Interpretation of treatment of relapsed/refractory multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China(2022 revision)].2022Zhonghua nei ke za zhi
  14. [The prognostic relationship between CD56 expression and newly diagnosed multiple myeloma].2022Zhonghua nei ke za zhi
  15. [Clinical analysis of 25 patients with non transplanted multiple myeloma who survived for more than 10 years].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  16. [MAS-like lesions and SIADH caused by bortezomib in the treatment of multiple myeloma : three cases report and literature review].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  17. [The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era].2022Zhonghua yi xue za zhi
  18. [Controversies on the diagnosis and treatment of relapsed/refractory multiple myeloma].2022Zhonghua yi xue za zhi
  19. [Clinical Analysis of 25 Non-Transplanted Multiple Myeloma Patients Treated with Bortezomib Maintenance].2021Zhongguo shi yan xue ye xue za zhi
  20. [Autologous stem cell transplantation improve the survival of newly diagnosed multiple myeloma patients].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status46
  1. Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omicsStatus unknownNCT04678089Lead sponsorStart 2019-05
  2. CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary PlasmacytomaStatus unknownNCT02336386Lead sponsorPhase 3Start 2014-12
  3. Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma PatientsStatus unknownNCT02981199Lead (inferred)N/AStart 2016-01
  4. Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM PatientsStatus unknownNCT02572596Lead (inferred)N/AStart 2013-01
  5. Study of YKST02 in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT07695740Study sitePhase 2Start 2027-12
  6. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  7. Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07529782Study sitePhase 1Start 2026-03
  8. Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMARecruitingNCT07620275Study sitePhase 1Start 2026-09
  9. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  10. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  11. A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingNCT07297329Study sitePhase 3Start 2025-12
  12. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06375044Study sitePhase 1Start 2024-05
  13. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsRecruitingNCT06508983Study sitePhase 3Start 2024-06
  14. A Study of YKST02 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06574568Study sitePhase 1Start 2024-06
  15. Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaRecruitingNCT05565807Study sitePhase 1/Phase 2Start 2023-02
  16. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Study sitePhase 3Start 2022-09
  17. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  18. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  19. A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT07266441Study sitePhase 2Start 2026-02
  20. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  21. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  22. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  23. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  24. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10
  25. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  26. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Study sitePhase 3Start 2021-01
  27. SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological MalignanciesActive, not recruitingNCT04684108Study sitePhase 1Start 2021-11
  28. A Study of NINLARO® in Chinese Adults With Multiple MyelomaActive, not recruitingNCT05013190Study siteStart 2021-10
  29. A Study of TQB3820 in Patients With Hematological MalignanciesStatus unknownNCT05020639Study sitePhase 1Start 2021-08
  30. Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and LymphomaStatus unknownNCT04818372Study sitePhase 1Start 2021-04
  31. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  32. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04674514Study sitePhase 1/Phase 2Start 2021-04
  33. Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MMStatus unknownNCT05052970Study sitePhase 1Start 2021-10
  34. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  35. A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662Study siteStart 2020-05
  36. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  37. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Study sitePhase 3Start 2019-01
  38. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Study sitePhase 2Start 2019-01
  39. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  40. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  41. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10
  42. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  43. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Study sitePhase 3Start 2017-03
  44. A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)CompletedNCT02312258Study sitePhase 3Start 2015-04
  45. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Study sitePhase 3Start 2013-07
  46. Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple MyelomaCompletedNCT00689936Study sitePhase 3Start 2008-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 2 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.05%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

22 hospitals in Beijing for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
    Phase
    Phase 1/Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05294731

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

10 hospitals in Beijing for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Detection of three common mutations causing β-thalassemia by using a closed-tube multiplex PCR.2018Experimental and molecular pathology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led no English-language PubMed papers on atypical haemolytic uraemic syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Beijing for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Beijing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 34 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.7%.

Papers led
34
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 8820212022: 5520222023: 101020232024: 5520242025: 662025

29 hospitals in Beijing for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    PCCT-Defined High-Risk Plaque and Future Coronary Events: The PREDICT Study
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT07822737

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Chao-Yang HospitalBeijing

  2. Not yet recruiting
    Comparison of RA-IVL and RA-SHP in Calcified Coronary Lesions
    Phase
    N/A
    Started
    2026-01
    Posted
    Registry
    NCT07279987

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Chao-Yang HospitalBeijing

  3. Recruiting
    CCTA Improves Clinical Management of Stable Chest Pain
    Phase
    Not given
    Started
    2016-01
    Posted
    Registry
    NCT04691037

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Chest Hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  4. Recruiting
    Registry of Multicenter Brain-Heart Comorbidity in China
    Phase
    Not given
    Started
    2012-01
    Posted
    Registry
    NCT05961748

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tiantan Hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Harbin, Shanghai, Zhengzhou

  5. Not yet recruiting
    Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
    Phase
    N/A
    Started
    2021-09
    Posted
    Registry
    NCT04995159

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 67 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huai'an, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Yinchuan, Zhanjiang, Zhengzhou, Zhongshan, Zhuhai, Zibo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineClinical trials / research unit
Papers it led34
  1. Plasma metabolomics disentangles T2DM- and CAD-specific dysmetabolism and identifies potential biomarkers for CAD risk escalation in diabetic patients.2025Cardiovascular diabetologyFree full text
  2. A Novel Technique of "Drag-Drill" for Retrograde Chronic Total Occlusion Revascularization in Heavily Calcified Tortuous Lesions: A Case Report.2025Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  3. Bioinformatics-focused identification of metabolomic Markers in coronary microvascular disease.2025Computers in biology and medicine
  4. Plasma SIRT7 as a novel biomarker for coronary artery disease and rehospitalization risk in hypertensive patients: a cross-sectional and longitudinal study.2025Internal and emergency medicineFree full text
  5. MAFLD as a predictor of adverse cardiovascular events among CHD patients with LDL-C<1.8 mmol/L.2025Nutrition, metabolism, and cardiovascular diseases : NMCD
  6. Evaluating the quality of TikTok videos on coronary artery disease using various scales to examine correlations with video characteristics and high-quality content.2025Scientific reportsFree full text
  7. Infarct-related artery only revascularization versus multi-vessel revascularization for patients with Killip I-IV acute myocardial infarction and multivessel disease.2024Acta cardiologica
  8. SYNTAX I score is associated with genetically confirmed familial hypercholesterolemia in chinese patients with coronary heart disease.2024BMC cardiovascular disordersFree full text
  9. Machine learning reveals serum myristic acid, palmitic acid and heptanoylcarnitine as biomarkers of coronary artery disease risk in patients with type 2 diabetes mellitus.2024Clinica chimica acta; international journal of clinical chemistry
  10. Alterations in the gut mycobiome with coronary artery disease severity.2024EBioMedicineFree full text
  11. LRG1 promotes atherosclerosis by inducing macrophage M1-like polarization.2024Proceedings of the National Academy of Sciences of the United States of AmericaFree full text
  12. Prognostic implications of stress hyperglycemia ratio in patients with myocardial infarction with nonobstructive coronary arteries.2023Annals of medicineFree full text
  13. Diagnostic potential of myocardial early systolic lengthening for patients with suspected non-ST-segment elevation acute coronary syndrome.2023BMC cardiovascular disordersFree full text
  14. Exploring an immune cells-related molecule in STEMI by bioinformatics analysis.2023BMC medical genomicsFree full text
  15. Declined plasma microfibrillar-associated protein 4 levels in acute coronary syndrome.2023European journal of medical researchFree full text
  16. TCH-165 attenuates cardiac ischaemia/reperfusion injury by balancing mitochondrial dynamics via increasing proteasome activity.2023European journal of pharmacology
  17. Predicting coronary plaque progression with conventional plaque parameters and radiomics features derived from coronary CT angiography.2023European radiology
  18. An examination of causal associations and shared risk factors for diabetes and cardiovascular diseases in the East Asian population: A Mendelian randomization study.2023Frontiers in endocrinologyFree full text
  19. Drug-coated balloons: A better revascularization strategy in patients with multivessel coronary artery disease undergoing one-stop hybrid coronary revascularization surgery.2023Kardiologia polska
  20. Metabolomic analysis reveals the metabolic disturbance in aortic dissection: Subtype difference and accurate diagnosis.2023Nutrition, metabolism, and cardiovascular diseases : NMCD
  21. Cinematic Rendering of Complex Coronary Artery Left Atrial Fistula.2023Radiology
  22. Sex Difference in the Association Between Neutrophil to Lymphocyte Ratio and Severity of Coronary Artery Disease.2022Angiology
  23. Frailty as a predictor of all-cause mortality in elderly patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis.2022Archives of gerontology and geriatrics
  24. Clinical value of resting cardiac dual-energy CT in patients suspected of coronary artery disease.2022BMC medical imagingFree full text
  25. Association of plasma Ninjurin-1 and SYNTAX score in patients with coronary artery disease.2022Clinical biochemistry
  26. Relation of Myocardial Perfusion Reserve and Left Ventricular Ejection Fraction in Ischemic and Nonischemic Cardiomyopathy.2022The American journal of cardiologyFree full text
  27. Risk factor analysis of acute kidney injury after one-stop hybrid coronary revascularization.2021Annals of palliative medicine
  28. MiR-339 is a potential biomarker of coronary heart disease to aggravate oxidative stress through Nrf2/FOXO3 targeting Sirt2.2021Annals of palliative medicine
  29. Predictive value of ACEF II score in patients with multi-vessel coronary artery disease undergoing one-stop hybrid coronary revascularization.2021BMC cardiovascular disordersFree full text
  30. Predictive value of CHADS2 and CHA2DS2-VASc scores for coronary artery lesions and in-hospital prognosis of patients with acute ST-segment elevation myocardial infarction.2021BMC cardiovascular disordersFree full text
  31. The long-term impact of a chronic total occlusion in a non-infarct-related artery on acute ST-segment elevation myocardial infarction after primary coronary intervention.2021BMC cardiovascular disordersFree full text
  32. Short-term outcomes of acute coronary involvement in type A aortic dissection without myocardial ischemia: a multiple center retrospective cohort study.2021Journal of cardiothoracic surgeryFree full text
  33. Long Non-coding RNA GAS5 Worsens Coronary Atherosclerosis Through MicroRNA-194-3p/TXNIP Axis.2021Molecular neurobiologyFree full text
  34. Value of territorial work efficiency estimation in non-ST-segment-elevation acute coronary syndrome: a study with non-invasive left ventricular pressure-strain loops.2021The international journal of cardiovascular imaging
All its trials on ClinicalTrials.gov, any status11
  1. PCCT-Defined High-Risk Plaque and Future Coronary Events: The PREDICT StudyRecruitingNCT07822737Lead sponsorStart 2025-01
  2. Safety and Efficacy Study of CYPHER® Sirolimus Stent and ENDEAVOR® Zotarolimus Stent in Patients With Acute ST Elevation Myocardial Infarction (STEMI) and Analysis of Current Status of Emergency PCI Green Channel for STEMI Patients in ChinaStatus unknownNCT00781716Lead sponsorN/AStart 2008-10
  3. Comparison of USCOM Cardiac Output and Continuous Thermodilution Cardiac OutputCompletedNCT00804778Lead sponsorStart 2006-03
  4. Comparison of RA-IVL and RA-SHP in Calcified Coronary LesionsNot yet recruitingNCT07279987Lead (inferred)N/AStart 2026-01
  5. Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS SystemNot yet recruitingNCT04995159Study siteN/AStart 2021-09
  6. CCTA Improves Clinical Management of Stable Chest PainRecruitingNCT04691037Study siteStart 2016-01
  7. Registry of Multicenter Brain-Heart Comorbidity in ChinaRecruitingNCT05961748Study siteStart 2012-01
  8. A Safety and Efficacy Study of Lepu® Drug Coated Balloon in Treatment of Coronary Small-vessel DiseaseStatus unknownNCT04953117Study siteN/AStart 2021-03
  9. Impact of Low-fat and Full-fat Milk on Lipids and Cardiac Function in Patients With Coronary Artery DiseaseCompletedNCT06542172Study siteN/AStart 2020-09
  10. Efficacy and Mechanism of TCCRP in Patients With Chronic Coronary Syndrome Under Fusion Cardiac Rehabilitation ModelStatus unknownNCT03936504Study siteN/AStart 2019-10
  11. International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)CompletedNCT01471522Study siteN/AStart 2012-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 3 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 002025

23 hospitals in Beijing for congenital heart disease207 hospitals in China for congenital heart disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07292896

    Age 18 years to 79 years (registered criteria)

    Led by First Hospital of China Medical University; 11 listed hospitals as study sitesBeijing, Changchun, Chengdu, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Scoliosis

脊柱侧弯

Led 40 of the 925 English-language PubMed papers on scoliosis with an author in mainland China, 2021–2025: 4.3%.

Papers led
40
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 8820212022: 9920222023: 6620232024: 6620242025: 992025

15 hospitals in Beijing for scoliosis107 hospitals in China for scoliosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery
    Phase
    Phase 4
    Started
    2026-04
    Posted
    Registry
    NCT07229495

    Age 10 years to 17 years (registered criteria)

    Led by Peking Union Medical College Hospital; 5 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led40
  1. Radiographic assessment and risk model of atlantoaxial instability induced by Halo-pelvic traction in treating severe spinal deformity.2026European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  2. Safety and efficacy of long spinal fusion to the pelvis for the treatment of neuromuscular scoliosis: single-arm meta-analysis and systematic review.2026Spine deformity
  3. The Safety and Effectiveness of Multi-Segment Cortical Bone Trajectory Screws in Adult Degenerative Scoliosis with Stenosis Among the Elderly: Minimum 5-year Follow-up Study.2025Clinical interventions in agingFree full text
  4. Development and validation of machine learning models for distal instrumentation-related problems in patients with degenerative lumbar scoliosis based on preoperative CT and MRI.2025European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  5. Percutaneous transforaminal endoscopic decompression versus posterior short-segment fusion for treating degenerative lumbar scoliosis with lumbar spinal stenosis: a cohort study with a minimum five year followup.2025International orthopaedics
  6. Safety and efficacy of robot-assisted technology in severe complex and non-severe spinal deformity correction: a retrospective comparative study.2025Journal of orthopaedic surgery and researchFree full text
  7. Impact of halo-pelvic traction duration on pulmonary improvement quantified by pulmonary function tests and three-dimensional lung reconstruction in severe rigid kyphoscoliosis: a prospective cohort study.2025Journal of orthopaedic surgery and researchFree full text
  8. Incidence and Risk Factors of Lumbosacral Complications Following Long-Segment Spinal Fusion in Adult Degenerative Scoliosis.2025Orthopaedic surgeryFree full text
  9. Machine learning analysis of cervical balance in early-onset scoliosis post-growing rod surgery: a case-control study.2025Scientific reportsFree full text
  10. Surgical Correction of Severe Scoliosis Leads to Changes in Central Airway Resistance Evaluated with CT-Based 3D Reconstruction and Impulse Oscillometry.2025The Journal of bone and joint surgery. American volume
  11. The efficacy and safety of intrawound vancomycin powder to prevent surgical site infection in adult scoliosis surgery (Vanco-SSIASS): study protocol for a prospective, randomized controlled, assessor‑blinded, open‑label, multicenter trial.2025TrialsFree full text
  12. Preoperative halo-gravity traction combined with one-stage posterior spinal fusion surgery following for severe rigid scoliosis with pulmonary dysfunction: a cohort study.2024BMC surgeryFree full text
  13. Answer to the letter to the editor of T. Ozudogru Celik concerning "greater pelvic obliquity in adolescent idiopathic scoliosis combined with hip dysplasia" by Zhao X, et al. (Eur Spine J [2024]: doi: 10.1007/s00586-023-08055-y).2024European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  14. Greater pelvic obliquity in adolescent idiopathic scoliosis combined with hip dysplasia.2024European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  15. Clinical outcomes of percutaneous transforaminal endoscopic decompression for the treatment of degenerative lumbar scoliosis associated with spinal stenosis in elderly individuals: a matched comparison study.2024International orthopaedics
  16. Factors associated with postoperative coronal imbalance in adult patients with severe and rigid scoliosis: a retrospective study.2024Journal of orthopaedic surgery and researchFree full text
  17. Precise execution of personalized surgical planning using three-dimensional printed guide template in severe and complex adult spinal deformity patients requiring three-column osteotomy: a retrospective, comparative matched-cohort study.2024Journal of orthopaedic surgery and researchFree full text
  18. Comparative efficacy and complications of single and dual growing rods for early-onset scoliosis: an updated meta-analysis.2023European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  19. Evaluation of bone mineral density in adolescent idiopathic scoliosis using a three-dimensional finite element model: a retrospective study.2023Journal of orthopaedic surgery and researchFree full text
  20. Surgical Treatment of Scoliosis Lenke Type 5, Anterior Versus Posterior, Which Approach is Better?: A Systematic Review and Meta-Analysis.2023Spine
  21. Evaluation of Pulmonary Function After Halo-Pelvic Traction for Severe and Rigid Kyphoscoliosis Utilizing CT with 3D Reconstruction.2023The Journal of bone and joint surgery. American volume
  22. Long-Term Radiographic and Pulmonary Function Outcomes After Dual Growing-Rod Treatment for Severe Early-Onset Scoliosis.2023The Journal of bone and joint surgery. American volume
  23. Postoperative complications following Schwab-grade-I versus Schwab-grade-II PCO in treating severe rigid kyphoscoliosis patients: comparative matched-group outcomes with minimum 2-year follow-up.2023The spine journal : official journal of the North American Spine Society
  24. The classification of coronal deformity based on preoperative global coronal malalignment for adult spinal deformity is questionable.2022BMC musculoskeletal disordersFree full text
  25. Elasticity change of the paravertebral fascia and muscle in adolescent idiopathic scoliosis after posterior selective fusion surgery.2022Clinical biomechanics (Bristol, Avon)
  26. Validity of the Roussouly classification system for assessing distal junctional problems after long instrumented spinal fusion in degenerative scoliosis.2022European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  27. Comparison of manual versus automated measurement of Cobb angle in idiopathic scoliosis based on a deep learning keypoint detection technology.2022European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  28. Scoliosis among children in Qinghai-Tibetan Plateau of China: A cross-sectional epidemiological study.2022Frontiers in public healthFree full text
  29. Posterior minimally invasive scoliosis surgery versus the standard posterior approach for the management of adolescent idiopathic scoliosis: an updated meta-analysis.2022Journal of orthopaedic surgery and researchFree full text
  30. Zebrafish and idiopathic scoliosis: the 'unknown knowns'.2022Trends in genetics : TIG
  31. Developments in Congenital Scoliosis and Related Research from 1992 to 2021: A Thirty-Year Bibliometric Analysis.2022World neurosurgery
  32. Developments, Focuses, and Trends in Early-Onset Scoliosis From 2005 to 2020: A Systematic Bibliometric Analysis.2022World neurosurgery
  33. What is the impact of scoliotic correction on postoperative shoulder imbalance in severe and rigid scoliosis.2021BMC musculoskeletal disordersFree full text
  34. Evaluation of changes in shoulder balance and prediction of final shoulder imbalance during growing-rod treatment for early-onset scoliosis.2021BMC musculoskeletal disordersFree full text
  35. Frailty as a risk factor for postoperative complications in adult patients with degenerative scoliosis administered posterior single approach, long-segment corrective surgery: a retrospective cohort study.2021BMC musculoskeletal disordersFree full text
  36. Posterior thoracolumbar hemivertebra resection and short-segment fusion in congenital scoliosis: surgical outcomes and complications with more than 5-year follow-up.2021BMC surgeryFree full text
  37. How helpful is the halo-gravity traction in severe spinal deformity patients?: A systematic review and meta-analysis.2021European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  38. The safety and efficacy of one-stage posterior surgery in the treatment of presumed adolescent idiopathic scoliosis associated with intraspinal abnormalities a minimum 3-year follow-up comparative study.2021European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  39. Traditional growing rod for early-onset scoliosis in high-altitude regions: a retrospective study.2021Journal of orthopaedic surgery and researchFree full text
  40. Will the COVID-19 pandemic increase the prevalence of idiopathic scoliosis?2021Medical hypotheses
All its trials on ClinicalTrials.gov, any status1
  1. Tegileridine for Postoperative Pain After Adolescent Scoliosis SurgeryRecruitingNCT07229495Study sitePhase 4Start 2026-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 3 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 002025

24 hospitals in Beijing for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineRheumatology & immunology
Papers it led3
  1. Predictors for pulmonary artery involvement in Takayasu arteritis and its cluster analysis.2023Arthritis research & therapyFree full text
  2. Analysis of clinical features between active and inactive patients of Takayasu's arteritis with pulmonary arteries involvement.2023International journal of cardiology
  3. Value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of pulmonary artery activity in patients with Takayasu's arteritis.2021European heart journal. Cardiovascular Imaging
Chinese-language papers (not in the count)1
  1. [Takayasu arteritis with pulmonary artery involvement initially presenting as community-acquired pneumonia].2023Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
Earlier papers (2016–2020)4
  1. Clinical and imaging manifestations of Takayasu's arteritis with pulmonary hypertension: A retrospective cohort study in China.2019International journal of cardiology
  2. [Pulmonary cavities with Takayasu arteritis: report of 3 cases and literature review].2018Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  3. Echocardiographic characteristics of pulmonary artery involvement in Takayasu arteritis.2017Echocardiography (Mount Kisco, N.Y.)
  4. [The analysis of the clinical records diagnosed as Takayasu's arteritis with pulmonary vascular involvement].2016Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
All its trials on ClinicalTrials.gov, any status1
  1. Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's ArteritisCompletedNCT03096275Study sitePhase 3Start 2017-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 13 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.3%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 8820232024: 2220242025: 112025

25 hospitals in Beijing for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Posted
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRheumatology & immunology
Papers it led13
  1. Immunological Features and Potential Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis.2025The clinical respiratory journalFree full text
  2. Identifying prothrombin and bone sialoprotein as potential drug targets for idiopathic pulmonary fibrosis.2024BMC pulmonary medicineFree full text
  3. Clinical manifestations and prognostic factors analysis of patients hospitalised with acute exacerbation of idiopathic pulmonary fibrosis and other interstitial lung diseases.2024BMJ open respiratory researchFree full text
  4. Mendelian randomization analysis suggests no causal influence of gastroesophageal reflux disease on the susceptibility and prognosis of idiopathic pulmonary fibrosis.2023BMC pulmonary medicineFree full text
  5. Cluster features in fibrosing interstitial lung disease and associations with prognosis.2023BMC pulmonary medicineFree full text
  6. Serum Rcn3 level is a potential diagnostic biomarker for connective tissue disease-associated interstitial lung disease and reflects the severity of pulmonary function.2023BMC pulmonary medicineFree full text
  7. MMP19 Variants in Familial and Sporadic Idiopathic Pulmonary Fibrosis.2023Lung
  8. Characteristics of Chest HRCT and pulmonary function tests in elderly-onset primary Sjögren syndrome with interstitial lung disease.2023MedicineFree full text
  9. TGFβ1-RCN3-TGFBR1 loop facilitates pulmonary fibrosis by orchestrating fibroblast activation.2023Respiratory researchFree full text
  10. Features of transbronchial lung cryobiopsy-diagnosed fibrotic hypersensitivity pneumonitis.2023The clinical respiratory journalFree full text
  11. Newly diagnosed non-small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis.2023Thoracic cancerFree full text
  12. Air pollution and hospitalization of patients with idiopathic pulmonary fibrosis in Beijing: a time-series study.2022Respiratory researchFree full text
  13. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.2021BMC pulmonary medicineFree full text
Chinese-language papers (not in the count)1
  1. [Research progress of occupational and environmental exposure and idiopathic pulmonary fibrosis].2022Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
Earlier papers (2016–2020)21
  1. Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling.2020BMC cancer
  2. HYAL1 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits HFL-1 Fibroblast Proliferation When Upregulated.2020BioMed research international
  3. Evaluation of health-related quality of life and the related factors in a group of Chinese patients with interstitial lung diseases.2020PloS one
  4. Mechanical ventilation for acute respiratory failure due to idiopathic pulmonary fibrosis versus connective tissue disease-associated interstitial lung disease: Effectiveness and risk factors for death.2020The clinical respiratory journal
  5. [Postinflammatroy pulmonary fibrosis of COVID-19: the current status and perspective].2020Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  6. [A concise review of telomere and telomerase-related genetic markers in fibrotic lung diseases].2020Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
  7. Independent Clinical Factors Relevant to Prognosis of Patients with Idiopathic Pulmonary Fibrosis.2019Medical science monitor : international medical journal of experimental and clinical research
  8. Clinical features and prognosis of microscopic polyangiitis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis.2019The clinical respiratory journal
  9. Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone.2019Therapeutic advances in respiratory disease
  10. A Rare Missense Variant in Telomerase Reverse Transcriptase is Associated with Idiopathic Pulmonary Fibrosis in a Chinese Han Family.2018Chinese medical journal
  11. Clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia.2018Clinical rheumatology
  12. Differentiating Usual Interstitial Pneumonia From Nonspecific Interstitial Pneumonia Using High-resolution Computed Tomography: The "Straight-edge Sign".2018Journal of thoracic imaging
  13. Incidence and radiologic-pathological features of lung cancer in idiopathic pulmonary fibrosis.2018The clinical respiratory journal
  14. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.2018The clinical respiratory journal
  15. [Real-life experience with pirfenidone in idiopathic pulmonary fibrosis].2018Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  16. Increased activated regulatory T cells proportion correlate with the severity of idiopathic pulmonary fibrosis.2017Respiratory research
  17. Fibrinolytic system related to pulmonary arterial pressure and lung function of patients with idiopathic pulmonary fibrosis.2017The clinical respiratory journal
  18. [Clinical features of acute diffuse pulmonary exudative disorders].2017Zhonghua yi xue za zhi
  19. [Differentially expressed genes analysis in expression profile data of pulmonary fibrosis with pulmonary hypertension].2017Zhonghua yi xue za zhi
  20. Phosphatase and tensin homolog deleted on chromosome 10 contributes to phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis via multiple pathways.2016Experimental biology and medicine (Maywood, N.J.)
  21. miR-130b-3p Modulates Epithelial-Mesenchymal Crosstalk in Lung Fibrosis by Targeting IGF-1.2016PloS one
All its trials on ClinicalTrials.gov, any status8
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  3. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  4. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09
  5. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  6. Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT04419558Study sitePhase 3Start 2020-09
  7. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06
  8. Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT01170065Study sitePhase 2Start 2010-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

15 hospitals in Beijing for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

20 hospitals in Beijing for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 112025

26 hospitals in Beijing for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 3 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025

15 hospitals in Beijing for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 2 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 2.0%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

10 hospitals in Beijing for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led 1 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Beijing for congenital diaphragmatic hernia44 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Beijing for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Chinese-language papers (not in the count)1
  1. [Current management status of hereditary colorectal cancer].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

首都医科大学附属北京朝阳医院

Beijing Chao-Yang Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Beijing Chaoyang Hospital; Beijing Chao-yang Hospital; Beijing Chaoyang Hospital Affiliated to Capital Medical University; Myeloma Research Center of Beijing Beijing Chao-Yang Hospital; Beijing Chao-yang Hospital Affiliated with Capital Medical University; Beijing Chao-yang Hospital Affiliated to Capital Medical University; Beijing Chaoyang Hospital Capital Medical University; Capital Medical University Beijing Chaoyang Hospital

Suggest a correctionDownload the data